PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
16789993-0	2006	Effect of CYP2C19 genetic polymorphism on pharmacokinetics of phenytoin and phenobarbital in Japanese epileptic patients using Non-linear Mixed Effects Model approach.	Phenobarbital	76-89	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	10-17	
16789993-1	2006	OBJECTIVE: To clarify the effect of genetic polymorphism of CYP2C19 on pharmacokinetics of phenytoin and phenobarbital using a Non-linear Mixed Effects Modelling analysis in Japanese epileptic patients.	Phenobarbital	105-118	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	60-67	
16789993-5	2006	The total body clearance of phenobarbital decreased by 19.3% in patients with CYP2C19*1/*3 or the poor metabolizers of CYP2C19 compared with patients with normal CYP2C19 or with CYP2C19*1/*2.	Phenobarbital	28-41	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	78-85	
16789993-5	2006	The total body clearance of phenobarbital decreased by 19.3% in patients with CYP2C19*1/*3 or the poor metabolizers of CYP2C19 compared with patients with normal CYP2C19 or with CYP2C19*1/*2.	Phenobarbital	28-41	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	119-126	
16789993-5	2006	The total body clearance of phenobarbital decreased by 19.3% in patients with CYP2C19*1/*3 or the poor metabolizers of CYP2C19 compared with patients with normal CYP2C19 or with CYP2C19*1/*2.	Phenobarbital	28-41	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	119-126	
16789993-5	2006	The total body clearance of phenobarbital decreased by 19.3% in patients with CYP2C19*1/*3 or the poor metabolizers of CYP2C19 compared with patients with normal CYP2C19 or with CYP2C19*1/*2.	Phenobarbital	28-41	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	119-126	
16789993-6	2006	CONCLUSION: These findings indicated that the genetic polymorphisms of CYP2C19 contribute to the pharmacokinetic variability of phenytoin and phenobarbital, the poor metabolizers of CYP2C19, which are relatively common in Asian groups.	Phenobarbital	142-155	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	71-78	
16789993-6	2006	CONCLUSION: These findings indicated that the genetic polymorphisms of CYP2C19 contribute to the pharmacokinetic variability of phenytoin and phenobarbital, the poor metabolizers of CYP2C19, which are relatively common in Asian groups.	Phenobarbital	142-155	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	182-189